Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

tivumecirnon (FLX475)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Hanmi, RAPT Therap

Drug class:

CCR4 receptor antagonist

Related drugs:

‹

mogamulizumab-kpkc (9)

mogamulizumab-kpkc (9)

›

CCR4 overexpression	Head and Neck Cancer	CCR4 overexpression	Head and Neck Cancer	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3
CCR4 overexpression	Head and Neck Cancer	CCR4 overexpression	Head and Neck Cancer	pembrolizumab + FLX475 Sensitive: C3 – Early Trials pembrolizumab + FLX475 Sensitive : C3	pembrolizumab + FLX475 Sensitive: C3 – Early Trials pembrolizumab + FLX475 Sensitive : C3
CCR4 overexpression	Nasopharyngeal Carcinoma	CCR4 overexpression	Nasopharyngeal Carcinoma	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3
CCR4 overexpression	Nasopharyngeal Carcinoma	CCR4 overexpression	Nasopharyngeal Carcinoma	pembrolizumab + FLX475 Sensitive: C3 – Early Trials pembrolizumab + FLX475 Sensitive : C3	pembrolizumab + FLX475 Sensitive: C3 – Early Trials pembrolizumab + FLX475 Sensitive : C3
CCR4 overexpression	Lymphoma	CCR4 overexpression	Lymphoma	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3	FLX475 Sensitive: C3 – Early Trials FLX475 Sensitive : C3